Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BRACE trial

- PMLiVE

RedHill Biopharma advances phase 2/3 COVID-19 programme

Submits clinical trial applications in Mexico and Brazil

- PMLiVE

EMA to support real-world monitoring of COVID-19 treatments/vaccines

New infrastructure will support real-world studies

- PMLiVE

China’s CanSino Biologics reveals phase 2 coronavirus vaccine results

Candidate induced neutralising antibody responses

- PMLiVE

Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales

AstraZeneca AZ

AZ/Oxford’s COVID-19 vaccine proves promising in early trials

Vaccine candidate produced robust immune response

- PMLiVE

UK agrees further COVID-19 vaccine deals with Pfizer/BioNTech, Valneva

Government has already agreed similar deal with AstraZeneca

- PMLiVE

UK biotech Synairgen reveals promising early results for COVID-19 drug

Phase 1 results show drug cuts risk of developing severe disease by 79%

- PMLiVE

GSK agrees on 10% equity stake in mRNA specialist CureVac

Equity investment totals £130m with an upfront payment of £104m

Article: Pricing a coronavirus vaccine

Using findings from Research Partnership's recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine. Read...

Research Partnership

- PMLiVE

Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

Includes 15 medicines from company's generics division

- PMLiVE

Healthineers’ COVID-19 antibody test proves most effective in comparative study

Beats tests from Roche, Abbott and DiaSorin

- PMLiVE

Moderna’s COVID-19 vaccine produces immune response in early trial

Antibodies observed in all participants tested

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links